Published in final edited form as:

J Rheumatol. 2010 January ; 37(1): 71–78. doi:10.3899/jrheum.090665.

PREMATURE AORTIC ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CONTROLLED TRANSESOPHAGEAL ECHOCARDIOGRAPHIC STUDY

Carlos A. Roldan, M.D. [Professor of Medicine],

Department of Medicine, Cardiology Division, University of New Mexico School of Medicine

Joseph Joson, M.D. [Senior Cardiology Fellow],

Department of Medicine, Cardiology Division, University of New Mexico School of Medicine

R.N. Janeen Sharrar,

Department of Medicine, Cardiology Division, University of New Mexico School of Medicine

Clifford R. Qualls, Ph.D. [Emeritus Professor], and

Mathematics and Statistics, University of New Mexico School of Medicine

Wilmer L. Sibbitt Jr., M.D. [Professor of Medicine]

Department of Medicine, Rheumatology Division, University of New Mexico School of Medicine

Cardiology and Rheumatology Divisions, Department of Medicine, University of New Mexico School of Medicine, Albuquerque New Mexico, USA.

Abstract

Objective—Premature carotid and coronary atherosclerosis are common in systemic lupus erythematosus (SLE), but data on aortic atherosclerosis (AA) are limited. Thus, using multiplane transesophageal echocardiography (TEE) we sought to determine the prevalence and clinical correlates of AA in patients with SLE.

Methods—Forty-seven patients with SLE (44 women, 38 ± 12 years) and 21 healthy controls (19 women, 34 ± 12 years) underwent clinical and laboratory evaluations and TEE to assess AA defined as aortic intima media thickness (IMT) >0.86 mm or plaques as $>50\%$ focal IMT thickening as compared with surrounding walls. TEE studies were interpreted by an experienced observer unaware of subjects' clinical data.

Results—The prevalence of abnormal aortic IMT, plaques, or both lesions was higher in patients as compared to controls (37%, 23%, and 43% versus 14%, 0%, and 14%, respectively, all $p = 0.02$). In patients, age at diagnosis of SLE was the only positive independent predictor of AA (OR 1.12 per year from diagnosis of SLE, 95% CI 1.04 - 1.19, $p = 0.001$) and cyclophosphamide therapy was the only negative independent predictor of AA (OR 0.186, 95% CI 0.153 - 0.95, $p = 0.04$, equivalent to 5.4 times less likely to develop AA).

Conclusions—Aortic atherosclerosis is common in young patients with SLE, is predicted by a later age at diagnosis of SLE, but is negatively correlated with cyclophosphamide therapy. Thus, early diagnosis and more aggressive immunosuppressive therapy may be required to decrease the development and progression of atherosclerosis in patients with SLE.

Keywords

Aorta; Atherosclerosis; Transesophageal Echocardiography; Systemic Lupus Erythematosus

INTRODUCTION

Cardiovascular and cerebrovascular diseases are common in patients with systemic lupus erythematosus (SLE), which substantially increase their morbidity and mortality (1-4). Patients with SLE have a higher prevalence of carotid plaques and coronary artery calcifications than matched controls (37% and 31% versus 7–15% and 9%, respectively) after controlling for traditional atherogenic risk factors (5-7). The SLE associated immune mediated systemic inflammation is believed to be the primary pathogenic or exacerbating factor for development of atherosclerosis (8-10). Aortic atherosclerosis (AA) in non-SLE populations is associated with carotid, coronary, and peripheral arterial atherosclerosis, which predicts a 2-5 fold increase in future cerebral, cardiac, and peripheral arterial ischemic events and mortality (11-15). In patients with SLE, AA may have similar clinical and prognostic implications. However, unlike carotid or coronary atherosclerosis, the prevalence of AA in patients with SLE is unknown. Therefore, this study was designed to determine the prevalence and clinical correlates of AA using multiplane transesophageal echocardiography (TEE) in patients with SLE as compared to age and gender matched healthy controls.

MATERIALS AND METHODS

Study populations

This study protocol was approved by the Institutional Review Board of the University of New Mexico and conformed to the Declaration of Helsinki. All subjects participated only after signing a written informed consent. Forty-seven consecutive patients with diagnosis of SLE according to the American Rheumatologic Association criteria, 44 women, with a mean age of 38 ± 12 years (range, 18-60) and 21 healthy volunteers, 19 women, with a mean age of 34 ± 12 years (range, 18-57) agreed to participate in the study. Patients with SLE were recruited from a well characterized population of ~200 patients between 18 and 60 years old regularly followed at the Rheumatology Clinics of the University of New Mexico Health Sciences Center. Subjects >60 years old with or without SLE were excluded due to the higher prevalence of atherosclerosis in this age group (16,17).

Clinical and laboratory evaluations

Patients with SLE and controls underwent general clinical and laboratory evaluations including specific parameters of inflammation, coagulation, and fibrinolysis. In addition, patients with SLE were well characterized regarding their demographics; traditional atherogenic risk factors; disease duration, activity, severity, and therapy; standard serology; and antiphospholipid antibody status.

Transesophageal Echocardiography

All subjects underwent multiplane TEE with Philips I-E33 systems (Andover Massachusetts) using a 7 MHz phased array transducer with an axial resolution of 0.1 mm. At a low depth (3-4 cm) and using a narrow sector scan to improve image lateral resolution, two dimensional guided M-mode images were used to assess IMT and plaques of the anterior wall of the aortic arch and proximal (at 25-30 cm from the incisors), mid (at 30-35 cm) and distal descending thoracic aorta (at 35-40 cm). Also, two-dimensional images were used to assess aortic IMT and plaques of the medial and lateral walls. Near field limited resolution precluded accurate assessment of the aortic posterior wall. Also, far field limited

resolution precluded an accurate assessment of IMT of the ascending aorta, but not of plaques. Measurements of IMT were performed from the aortic short and long axis views and during end-diastole after the electrocardiographic P wave. All studies were digitally stored and quantitatively measured off line using electronic callipers. At each aortic level, 3-6 measurements (from short and long axis views) of the anterior IMT were averaged to determine the mean $\pm$ 1SD, minimum, and maximum aortic IMT values. All studies were codified and studies of patients and controls were randomly intermixed and interpreted by an experience observer unaware of subjects' clinical data. **Criteria for interpretation.** In the absence of reported IMT values in healthy subjects, AA was defined as abnormal aortic IMT as >0.86 mm (value corresponding to the mean in normal controls plus 1.5 standard deviation and which in an receiver operating curve provided a specificity of 91%) or plaques defined as $>50\%$ focal or protruding wall thickening as compared with surrounding walls (5,18,19) (Figure 1).

Statistical Analysis

Student's *t* test or Wilcoxon rank-sum test (for non-normally distributed data) and Fisher's exact test were used for comparison of continuous and categorical variables among groups, respectively. Univariate and multivariate logistic regression analyses were performed to determine independent effects of clinical and laboratory variables on AA. Odds ratios and 95% confidence intervals were reported. A 2-tailed *p* value less than 0.05 was considered significant.

RESULTS

Characteristics of Patients and Controls (Table 1)

Patients had higher systolic, diastolic, and mean arterial blood pressures, smoked more, had lower hemoglobin, worse renal function and proteinuria, lower albumin, and higher tPA than controls (all *p* < 0.05). Other parameters of inflammation, coagulation, and fibrinolysis were similar in patients and controls. Specific clinical, therapeutic, and serologic parameters of SLE are delineated in Table 2.

Aortic intima-media thickness and prevalence of aortic atherosclerosis in patients and controls

Aortic IMT values at the proximal and mid levels of the descending aorta and arch were significantly higher in patients than in controls (all *p* < 0.01 , Table 3). The distal descending aorta showed a trend toward significance (*p* = 0.07). Also, the overall mean and maximum IMT values were higher in patients as compared to controls (both *p* < 0.002). In both groups, but significantly more in patients with SLE, aortic IMT increased with age (Figure 2). Of most importance, the overall prevalence of abnormal aortic IMT, plaques, or both lesions was higher in patients than in controls (37%, 23%, and 43% versus 14%, 0%, and 14%, respectively, all *p* < 0.02 , Table 3).

Predictors of aortic atherosclerosis in patients and controls

In multivariate analyses that included all demographic, clinical, and laboratory variables delineated in Table 1, only age and SLE disease were independent predictors of AA [odds ratio (OR) of 1.08 per year of age increment, 95% confidence interval (CI) of 1.025 to 1.4, *p* = 0.004; and OR of 6.7 for the SLE group, 95% CI of 1.28 to 35, and *p* = 0.02, respectively] (Figure 2).

Predictors of aortic atherosclerosis in patients with SLE (Table 4)

In univariate analyses that included all variables delineated in Tables 1 and 2, only age and age at diagnosis of SLE were positive predictors of AA (OR 1.08 per year of age, CI 1.02 to 1.14, $p = 0.009$, and OR 1.12 per year from age at diagnosis of SLE, CI 1.04 to 1.19, $p = 0.001$, respectively). Cyclophosphamide therapy was a negative predictor of AA (OR 0.172, CI 0.045 to 0.655, $p = 0.01$, equivalent to 5.8 times less likely to develop AA). In a multivariate analyses, only age at diagnosis of SLE and cyclophosphamide therapy were independent predictors of AA (OR = 1.12 per year from age at diagnosis of SLE, 95% CI 1.043 to 1.2, $p = 0.001$ and OR 0.19, 95% CI 0.15 - 0.95, $p = 0.04$, equivalent to 5.4 times less likely to develop AA on cyclophosphamide therapy) (Figure 3).

DISCUSSION

Major findings

There are three major findings in this study: 1) aortic IMT values in patients with SLE are higher than in gender and age matched controls; 2) the prevalence of AA is also higher in patients with SLE than in matched controls; and 3) age at diagnosis of SLE is the strongest independent positive predictor and cyclophosphamide therapy the independent negative predictor of AA. Therefore, SLE-associated chronic immune-mediated inflammation is an important independent primary or a potentiating pathogenic factor on age and traditional atherogenic risk factors for development or progression of atherosclerosis (3,5,7-9,20-22). Other series have demonstrated equivalent prevalence of subclinical carotid and coronary atherosclerosis in SLE (3,5,7). In this study, the later the age at diagnosis of SLE was, the higher the likelihood of developing AA. In contrast, cyclophosphamide therapy had a protective effect. These findings emphasize the importance of inflammation in the pathogenesis of AA and the need of an early diagnosis and aggressive treatment of SLE (5,6,23).

In this study, the lack of an independent association of other specific SLE parameters of inflammation with AA may be explained by two factors. First, this SLE cohort was aggressively treated with cyclophosphamide and/or antimetabolites when inflammation was present rather than relying on antimalarials and corticosteroids. Second, inflammation in SLE is variable over time and atherosclerosis likely results from the cumulative effects of inflammation over many years, thus, more aggressive and prolonged non-corticosteroid immunosuppression may have more effective anti-atherogenic effect than traditional time delimited approaches. Also in this study, traditional atherogenic risk factors were not statistical independent predictors of AA. However, these factors likely play an important exacerbating biologic effect on immune-mediated inflammation for the pathogenesis or progression of AA in SLE (5,6,24).

In non-SLE populations, a strong association has been demonstrated between moderate to severe degrees of AA (IMT >4mm or protruding atheromas) and coronary and cerebrovascular disease (11-15). In these series, AA has shown to be a marker of generalized atherosclerosis and a predictor of a 2-5 fold increased risk of future acute coronary syndromes, stroke or transient ischemic attacks, and cardiac or cerebrovascular mortality. In addition, AA has been proposed to be a substrate for cerebral and peripheral atheroemboli. Thus, AA exacerbated by hypercoagulability in patients with SLE may not only be a marker of coronary and cerebral atherosclerosis, but also a pathogenic factor for cardiac, cerebral, and peripheral arterial thrombotic or thromboembolic ischemic events. In fact, some series have reported the association of AA with aortic aneurysms or peripheral arterial disease with claudication or ischemic events requiring amputation of digits or extremities (25-28).

Comparison with previous studies

No prior study was found in the literature assessing AA in patients with SLE. However, the 43% prevalence of AA found in this study is similar to the reported rates of carotid plaques by ultrasonography (37.1%) and coronary artery calcification (31%) by electron beam computed tomography (5,6). Also in these and other series, SLE was an independent predictor of atherosclerosis (OR 6.7, CI 1.28 - 35, $p = 0.02$), patients with atherosclerosis were diagnosed at a later time and cyclophosphamide therapy had a protective effect (29-31). In addition, as in other series specific markers of inflammation and antiphospholipid antibodies were not temporally associated with AA. In contrast to previous series, our patient population was younger (mean age 38 ± 12 years) and therefore the observable effects of aging, long-term hyperlipidemia and of other traditional risk factors for atherosclerosis were reduced. **Pathogenesis of atherosclerosis in SLE.** The following interrelated mechanisms lead to the development of atherosclerosis in patients with SLE (5,8-10,20-22,24,32,33): 1) active cellular and humoral immunity result in activation of macrophages, lymphocytes, phagocytes, and neutrophils, CD4+CD28- and CD36 T-cells, and dendritic cells. These cytotoxic cells (either circulating or endovascularly adhered) cause platelets to release platelet derived growth factors and thromboxane A2 (a vasoconstrictor and platelet activator) and a decreased in endothelial cells production of nitric oxide and prostacyclin (PGI₂), all resulting in vasoconstriction and/or thrombosis. 2) Cytotoxic cells also produce multiple cytokines (granulocyte or monocyte colony stimulating factors, interferon- α , β , or γ , interleukins, tumor necrosis factor α or β , and macrophages migration inhibition factor), which are pro-inflammatory, chemotactic, increase proliferation of smooth muscle cells, and further activate macrophages with release of free radicals, matrix metalloproteinases, and elastase. Elastase causes elastin degradation and release of fibroblast growth factors. 3) Mononuclear and endothelial cell activation increased production of chemokines (heat shock proteins, CRP, rheumatoid factor), which recruit inflammatory cells, up regulate endothelial production of vascular and intercellular adhesion molecules, which further promote adhesion of inflammatory cells, vascular smooth cell proliferation, oxidative stress, endothelial dysfunction and apoptosis, extracellular matrix and collagen deposition. 4) Endothelial dysfunction increased production of pro-inflammatory HDL, oxidative LDL, and activation of the renin-angiotensin system. Finally, 5) SLE disease or steroid therapy related hypertriglyceridemia, hypercholesterolemia, homocysteinemia, and insulin resistance. These pathogenetic mechanisms result in endothelial dysfunction and apoptosis, smooth muscle cells proliferation, aortic wall hypertrophy and fibrosis, aortic stiffness, increase in arterial impedance, and ultimately in atherosclerosis.

Limitations of the study

1) Our patient population represents about 30% of ~200 potentially eligible patients from a tertiary care center. Thus, the prevalence of AA found in this study may be an over or underestimation as compared to that of a general SLE population; 2) limited visualization of the aortic posterior wall by TEE may have lead to underestimation of AA; 3) our age and gender matched healthy control group was small and therefore may have contributed to an overestimation of the independent effect of SLE on AA; and 4) the cut-off value of 0.87 mm used for defining abnormal IMT may have caused an overestimation of AA. However, the prevalence of AA using a cut-off of >1 mm showed similar prevalence of abnormal IMT (34% versus 10%, $p = 0.04$) and an overall similar prevalence of AA among groups (36% versus 10%, $p = 0.04$) (Figure 4). **Clinical implications of the study.** 1) SLE-associated chronic immune-mediated inflammation may promote premature large vessel atherosclerosis as it does for medium size carotid and coronary atherosclerosis; 2) an earlier diagnosis and aggressive anti-inflammatory therapy of SLE using non-corticosteroid immunosuppressives may prevent the development and progression of atherosclerosis; 3) AA may play a

pathogenic role in peripheral arterial thrombotic or thromboembolic ischemic disease in SLE; 4) subclinical AA may exacerbate aortic stiffness, hypertension, and increased left ventricular mass and diastolic dysfunction in SLE (34-36); and 5) antiplatelet and statin therapy may have a primary and secondary protective effects in SLE (37,38). These diagnostic and therapeutic interventions may decrease the current 2–3 fold increased morbidity and mortality of SLE patients with coronary, cerebrovascular, or peripheral arterial disease. However, a larger cross-sectional and longitudinal study is necessary to better define the short and long term clinical, therapeutic, and prognostic implications of AA in SLE.

Acknowledgments

Research supported by the grant RO1 HLO77422-01-A3 from the National Institutes of Health, NHLBI.

REFERENCES

1. Nossent J, Cikes N, Kiss E, Marchesoni A, Nasonova V, Mosca M, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. *Lupus*. 2007; 16:309–17. [PubMed: 17576731]
2. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. *Clin Exp Rheumatol*. 2008; 26(5 Suppl 51):S72–9. [PubMed: 19026147]
3. Becker-Merok A, Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. *Lupus*. 2009; 18:508–15. [PubMed: 19395452]
4. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. *J Rheumatol*. 2000; 27:1892–1895. [PubMed: 10955329]
5. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med*. 2003; 349:2399–2406. [PubMed: 14681505]
6. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med*. 2003; 349:2407–15. [PubMed: 14681506]
7. Jimenez S, Garcia-Criado MA, Tassies D. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. *Rheumatology (Oxford)*. 2005; 44:756–6. [PubMed: 15757967]
8. Rahman A, Isenberg D. Mechanisms of disease: Systemic lupus erythematosus. *N Engl J Med*. 2008; 358:929–39. [PubMed: 18305268]
9. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochem Pharmacol*. May 3.2009
10. Roldan CA. Valvular and coronary heart disease in systemic inflammatory diseases: Systemic Disorders in heart disease. *Heart*. 2008; 94:1089–101. [PubMed: 18625800]
11. Sen S, Hinderliter A, Sen PK, Simmons J, Beck J, Offenbacher S, et al. Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. *Circulation*. 2007; 116:928–35. [PubMed: 17684150]
12. Leys D, Woimant F, Ferrières J, Bauters C, Touboul PJ, Guérillot M, et al. DETECT Investigators. Detection and management of associated atherothrombotic locations in patients with a recent atherothrombotic ischemic stroke: results of the DETECT survey. *Cerebrovasc Dis*. 2006; 21:60–6. [PubMed: 16330865]
13. Tanaka M, Yasaka M, Nagano K, Otsubo R, Oe H, Naritomi H. Moderate atheroma of the aortic arch and the risk of stroke. *Cerebrovasc Dis*. 2006; 21:26–31. [PubMed: 16282686]
14. Varga A, Gruber N, Forster T, Piros G, Havasi K, Jebelovszki E, et al. Atherosclerosis of the descending aorta predicts cardiovascular events: a transesophageal echocardiography study. *Cardiovasc Ultrasound*. 2004; 22:2–21.

15. Tunick PA, Kronzon I. Embolism from the Aorta: Atheroemboli and Thromboemboli. *Curr Treat Options Cardiovasc Med.* 2001; 3:181–186. [PubMed: 11341863]
16. O’Leary D, Polak J, Kronmal R, Manolio T, Burke G, Wolfson S. Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med.* 1999; 340:14–21. [PubMed: 9878640]
17. Gratama JW, van Leeuwen RB. Abdominal aortic aneurysm: high prevalence in men over 59 years of age with TIA or stroke, a perspective. *Abdom Imaging.* May 22.2009
18. Osranek M, Pilip A, Patel PR, Molisse T, Tunick PA, Kronzon I. Amounts of aortic atherosclerosis in patients with aortic stenosis as determined by transesophageal echocardiography. *Am J Cardiol.* 2009; 103:713–7. [PubMed: 19231339]
19. Ono K, Kawasaki M, Tanaka R, Segawa T, Matsuo H, Watanabe S. Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. *Ultrasound Med Biol.* 2009; 35:193–200. [PubMed: 18977068]
20. Valdivielso P, Gómez-Doblas JJ, Macias M, Haro-Liger M, Fernández-Nebro A, Sánchez-Chaparro MA, et al. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. *Clin Exp Rheumatol.* 2008; 26:827–33. [PubMed: 19032815]
21. Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). *Autoimmun Rev.* 2009; 8:309–15. [PubMed: 18976721]
22. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, Shah N, et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. *Exp Biol Med (Maywood).* 2009; 234:354–60. [PubMed: 19144874]
23. Doria A, Arienti S, Rampudda M, Canova M, Tonon M, Sarzi-Puttini P. Autoimmun Rev. Preventive strategies in systemic lupus erythematosus. 2008; 7:192–7.
24. de Carvalho JF, Bonfá E, Borba EF. Systemic lupus erythematosus and “lupus dyslipoproteinemia”. *Autoimmun Rev.* 2008; 7:246–50. [PubMed: 18190886]
25. Sato J, Kawakami T, Nakabayashi K, Fukuoka K, Hirano K, Terado Y, et al. Multiple aortic aneurysms complicated by a rupture in the systemic lupus erythematosus: a case report. *Pathol Res Pract.* 2008; 204:845–50. [PubMed: 18653288]
26. Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yin J, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. *Semin Arthritis Rheum.* 2008; 38:124–31. [PubMed: 18206213]
27. Fernández M, Calvo-Alén J, Bertoli AM, Bastian HM, Fessler BJ, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. *J Clin Rheumatol.* 2007; 13:261–5. [PubMed: 17921793]
28. da Rocha MC, Vilar MJ, Freire EA, Santiago MB. Arterial occlusion in systemic lupus erythematosus: a good prognostic sign? *Clin Rheumatol.* 2005; 24:602–5. [PubMed: 15902521]
29. Telles RW, Lanna CC, Ferreira GA, Souza AJ, Navarro TP, Ribeiro AL. Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting. *Lupus.* 2008; 17:105–13. [PubMed: 18250133]
30. Belizna CC, Richard V, Primard E, Kerleau JM, Cailleux N, Louvel JP, et al. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. *Semin Arthritis Rheum.* 2008; 37:373–80. [PubMed: 17977581]
31. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum.* 2007; 56:3412–9. [PubMed: 17907140]
32. Tani C, Mosca M, d’Ascanio A, Versari D, Virdis A, Ghiadoni L, et al. Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD. *Reumatismo.* 2006; 58:212–8. [PubMed: 17013438]

33. Santos LL, Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. *Clin Chim Acta*. 2009; 399:1–7. [PubMed: 18838066]
34. Cacciapaglia F, Zardi EM, Coppolino G, Buzzulini F, Margiotta D, Arcarese L, et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. *Lupus*. 2009; 18:249–256. [PubMed: 19213864]
35. Bjarnegård N, Bengtsson C, Brodzski J, Sturfelt G, Nived O, Länne T. Increased aortic pulse wave velocity in middle aged women with systemic lupus erythematosus. *Lupus*. 2006; 15:644–50. [PubMed: 17120590]
36. Yildiz M, Yildiz BS, Soy M, Tutkan H. Impairment of arterial distensibility in premenopausal women with systemic lupus erythematosus. *Kardiol Pol*. 2008; 66:1194–9. [PubMed: 19105096]
37. Avalos I, Chung CP, Oeser A, Milne GL, Borntrager H, Morrow JD, et al. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. *Lupus*. 2007; 16:981–6. [PubMed: 18042592]
38. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. *Rheumatology (Oxford)*. 2007; 46:1560–5. [PubMed: 17693444]

Figure 1. Aortic Intima-Media Thickening and Plaques by TEE

A, B. Short axis (A) and long axis (B) two-dimensional guided M-mode images of the anterior wall at the mid level (30 cm) of the descending thoracic aorta (Ao) demonstrating normal intima media thickness (IMT) of <8mm (arrows) in a 50 year old woman with SLE. C,D. Two-dimensional guided M-mode images in a 48 year old woman with SLE demonstrating a well defined aortic plaque of 3.3 mm at the proximal (C, arrow) and abnormal IMT of 1.2 mm at the distal (D, arrow) descending thoracic aorta.

Figure 2. Aortic Atherosclerosis Versus Age by Group

By multivariate analyses, age and SLE disease were the only independent predictors of AA [odds ratio (OR) 1.08 per year of age increment, 95% confidence interval (CI) 1.025 - 1.4, $p = 0.004$ for age effect; and OR 6.7, CI 1.28 - 35, and $p = 0.02$, for group (SLE) effect]. Note that the probability of AA in patients with SLE was 40% at age 40 and 80% at age 60 as compared to 10% and 40%, respectively, in controls.

Figure 3. Aortic Atherosclerosis Versus Age at Diagnosis of SLE by Cyclophosphamide Therapy
 In patients with SLE and by multivariate analyses, age at diagnosis of SLE was the only independent positive predictor and cyclophosphamide (CTX) therapy was the only independent negative predictor of AA (OR = 1.118 per year from diagnosis of SLE, 95% CI 1.037 - 1.2, $p = 0.004$ and OR 0.186, CI 0.039 - 0.875, $p = 0.03$, equivalent to 5.4 times less likely to develop AA). Note that the probabilities of AA in patients with no cyclophosphamide therapy were nearly 40% at age 20, 80% at age 40, and almost 100% at age 60 as compared to nearly 10% at age 20, 40% at age 40, and 70% at nearly age 60 in patients on cyclophosphamide therapy.

Figure 4. Aortic Atherosclerosis Defined as Intima Media Thickening (>1 mm) or Plaques Versus Age by Group

By multivariate analyses, age and SLE disease were the only independent predictors of AA [odds ratio (OR) 1.08 per year of age increment, 95% confidence interval (CI) 1.025 - 1.4, $p = 0.005$ for age effect; and OR 6.7, CI 1.28 - 35, and $p = 0.03$, for group (SLE) effect]. Note that the probability of AA in patients with SLE was 40% at age 40 and 75% at age 60 as compared to 5% and nearly 35%, respectively, in controls.

Table 1

Clinical and Laboratory Data in Patients with SLE and Controls

Parameter	Patients (N = 47)	Controls (N = 21)	P Value
Age (years)	38 ± 12 (18-60)	37±12 (18-57)	0.17
Female gender (%)	94%	90%	0.64
Non hispanic whites and Hispanic (%)	36% and 55%	38% and 48%	0.81
Body mass index	27 ± 6	26 ± 5	0.41
Systolic blood pressure (mmHg)	125 ± 14	117 ± 9	0.008
Diastolic blood pressure (mmHg)	77 ± 10	73 ± 6	0.05
Mean arterial blood pressure (mmHg)	93 ± 10	88 ± 6	0.01
*Smoking (%)	53%	24%	0.03
Hemoglobin (g/dL)	13.3 ± 1.6	14 ± 1.5	0.04
Platelets (k/mm ³)	251 ± 96.7	268 ± 41	0.36
White blood cell count (k/mm ³)	5.6 ± 2.2	6.5 ± 1.8	0.08
Cholesterol (mg/dL)	184 ± 45	185 ± 45	0.95
Triglycerides (mg/dL)	153 ± 78	156 ± 103	0.91
Creatinine (mg/dL)	0.83 ± 0.33	0.73 ± 0.11	0.05
Proteinuria (mg/dL)	50 ± 117	3.5 ± 8	0.01
Glucose (mg/dL)	90 ± 21	82.6 ± 9	0.13
Albumin (g/dL)	3.9 ± 0.6	4.3 ± 0.3	0.007
P-selectine (ng/mL)	42 ± 20.45	39 ± 16	0.49
C3a(pg/mL)	2301 ± 3317	2096 ± 2218	0.77
C5a (pg/mL)	31.6 ± 10.7	29 ± 9.8	0.37
Quantitative D-dimer	1.01 ± 3.2	0.33 ± 0.39	0.17
tPA (ng/mL)	10.3 ± 6.6	7.6 ± 4.4	0.05
PAI-1 (U/mL)	9.7 ± 12.5	17.3 ± 37	0.36
Peak thrombin generation (nmol/L)	390.8 ± 133.5	440 ± 136.5	0.19
Thrombin-antithrombin complexes (ng/mL)	7.5 ± 10	5.8 ± 7	0.45
Platelet derived CD41 microparticles (uL)	552.9 ± 668	517 ± 592	0.83
Monocyte derived CD41 microparticles (uL)	441.7 ± 668	476.7 ± 486.6	0.81
Endothelium derived CD144 microparticles (uL)	161.6 ± 235	154 ± 122	0.87

* Defined as any amount of smoking for any duration of time.

tPA = tissue plasminogen antigen, PAI = plasminogen activator inhibitor

Table 2

Clinical and Laboratory Data in Patients with SLE

Characteristic	Patients (N = 47)
	Mean $\pm$ SD, (%)
Duration of SLE	8.9 $\pm$ 7.3 (range 1-31)
Age at diagnosis of SLE	29.5 $\pm$ 12.6 (range 10-56)
Smoking ($\geq$ 10pk/years)	30%
Hypertension (SBP $\geq$ 140 and DBP $\geq$ 90 mmHg)	16%
Diabetes mellitus (fasting glucose $\geq$ 130 mg/dL or on therapy)	4%
Hyperlipidemia (cholesterol $\geq$ 240 or Triglycerides $\geq$ 150 mg/dL)	45%
Any atherosclerotic risk factor (%)	70%
Postmenopausal status	9%
Total SLEDAI (U)	12 $\pm$ 10.4 (range, 1 – 47)
Total SLICC (U)	3.3 $\pm$ 2.4
Prednisone therapy	87%
Prednisone average dose (mg/d)	7.5 $\pm$ 7.3 (range, 0 – 40)
Prednisone (years)	7.2 $\pm$ 6.7 (range, 0 – 30)
Cyclophosphamide therapy	30%
Years of cyclophosphamide therapy	0.64 $\pm$ 0.90 (range 0 – 3)
Mycophenolate or methotrexate therapy	17%
Hydroxychloroquine or chloroquine therapy	47%
Aspirin, warfarin, or clopidogrel	21%
DNA titer (dilutions)	31.6 $\pm$ 50
ANA titer (dilutions)	353 $\pm$ 447
Antiphospholipid antibody positive	57%
IgM anticardiolipin antibody (IU)	9.3 $\pm$ 15
IgG anticardiolipin antibody (IU)	12.6 $\pm$ 19
IgA anticardiolipin antibody (IU)	5.9 $\pm$ 11.7
Smith antibody positive	30%
SSA antibody positive	40%
C3 (mg/dL)	99.4 $\pm$ 3.6
C4 (mg/dL)	20.8 $\pm$ 25.3
CH50 (mg/dL)	84.4 $\pm$ 36.4
C-reactive protein (mg/dl)	1.13 $\pm$ 1.5
Erythrocyte sedimentation rate (mm/hr)	24.6 $\pm$ 25.7

Data presented as mean $\pm$ SD; SLEDAI = SLE disease activity index; SLICC = SLE International Collaborating Clinics Damage Index

Table 3

Aortic Intima Media Thickness, Abnormal Intima Media Thickening, and Plaques in Patients with SLE and Controls

	Patients (N = 47)	Controls (N = 21)	P Value
Aortic Level (anterior wall)	Intima Media Thickness (mm), Mean Minimum, Maximum)		
Distal (35-40 cm)	0.83 ± 0.34 (0.47, 2.35)	0.71 ± 0.17 (0.47, 1.23)	0.07
Mid (30-35 cm)	0.95 ± 0.66 (0.47, 4.23)	0.67 ± 0.20 (0.47, 1.3)	0.01
Proximal (25-30cm)l	0.82 ± 0.27 (0.47, 1.57)	0.66 ± 0.19 (0.47, 1.27)	0.01
Arch l	0.86 ± 0.29 (0.53, 1.83)	0.65 ± 0.12 (0.40, 0.93)	0.001
Overall aortic IMT (Maximum)	1.11 ± 0.68 (0.57, 4.23)	0.76 ± 0.19 (0.55, 1.30)	0.002
Overall aortic IMT (Mean)	0.86 ± 0.27 (0.51, 1.89)	0.67 ± 0.15 (0.49, 1.13)	0.001
	Aorta Intima Media Thickening		
Distal (35-40 cm)	15/46 (33%)	3 (14%)	0.15
Mid (30-35 cm)	17/46 (37%)	3 (14%)	0.09
Proximal (25-30 cm)	15/46 (33%)	3 (14%)	0.14
Arch	13/34 (38%)	1/19 (5%)	0.01
Any aortic portion	17 (37%)	3 (14%)	0.02
	Aortic Plaque		
Distal (35-40 cm)	4/43 (9%)	0/20	0.21
Mid (30-35 cm)	4/42 (10%)	0/20	0.39
Proximal (25-30 cm)	4/42 (10%)	0/20	0.39
Arch	6/44 (14%)	0	0.17
Ascending aorta	1/47 (2%)	0	1.0
Any aortic portion	11 (23%)	0	0.01
	Aortic Intima Media Thickening or Plaque		
Any aortic portion	20 (43%)	3 (14%)	0.02

Table 4

Predictors of Aortic Intima-Media Thickening or Plaques in Patients with SLE

Univariate Analyses			
Variable	Odds Ratio	95% CI	P value
Age	1.08 per year	1.020 - 1.14	0.009
Age at diagnosis of SLE	1.12 per year	1.04 - 1.19	0.001
Cyclophosphamide therapy	0.17	0.045 – 0.655	0.01
Multivariate Analyses			
Age at diagnosis of SLE	1.12 per year	1.037 - 1.21	0.001
Cyclophosphamide therapy	0.19	0.153 - 0.95	0.03